Opportunity for Significant Investors in ADMA Biologics Class Action Lawsuit Organized by Rosen Law Firm

A Call to Action for ADMA Biologics Investors

The Rosen Law Firm, a prominent global law firm specializing in investor rights, is calling on individuals who purchased ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024, and March 25, 2026. This period marks what is known as the 'Class Period', and it is critical for those investors to take note of a pivotal deadline.

Important Deadline Approaching

August 10, 2026, serves as a significant date for investors. This is the deadline to become a lead plaintiff in the ongoing securities fraud class action lawsuit initiated by the Rosen Law Firm. Participating in this class action does not require any upfront payment as the firm operates on a contingency fee basis.

Eligibility for the Class Action

If your losses from ADMA Biologics securities during the Class Period exceed $100,000, you may be eligible for compensation. This class action aims to protect the rights of investors who might have been misled by the company's practices. Rosen Law Firm encourages affected investors to contact them or visit their website to join the class action and learn more about the process.

Investors are invited to reach out to Phillip Kim, Esq., toll-free at 866-767-3653, or email [email protected] for more details about this lawsuit. Those looking to act as lead plaintiffs must file their motions by the aforementioned deadline.

Why Choose Rosen Law Firm?

Rosen Law Firm has a successful track record representing investors globally, particularly in cases involving securities class actions and shareholder derivative lawsuits. They have notably secured the largest securities class action settlement against a Chinese company and have consistently ranked at the top for the number of settlements. In 2019 alone, they recovered over $438 million for their clients.

Additionally, many attorneys within the firm have received accolades from noteworthy organizations such as Lawdragon and Super Lawyers, showcasing their expertise in this niche area of law.

The Allegations Against ADMA Biologics

According to the details emerging from the filed lawsuit, multiple allegations have surfaced against ADMA Biologics. These include claims that the company:
1. Engaged in undisclosed related party transactions,
2. Utilized channel stuffing to artificially inflate revenue,
3. Lacked adequate internal controls.

These misstatements and failures allegedly led to a series of false claims regarding the company’s operations and overall health. As the truth came to light, investors suffered significant financial damages.

Next Steps for Interested Investors

To become part of the ADMA Biologics class action, investors are advised to visit the following link: rosenlegal.com/cases/adma-biologics-inc/join. Initial participation does not require any legal action unless you opt to serve as lead plaintiff.

Final Thoughts

Investors holding significant losses from their investments in ADMA Biologics should act promptly to protect their rights. This lawsuit represents an opportunity to seek justice and potential financial recuperation for the losses endured. For updated information, follow Rosen Law Firm on their social media platforms or reach out for direct inquiries. Remember, while no class has been certified yet, your eligibility to partake in any future recovery does not depend on serving as a lead plaintiff. Join in and ensure that your voice is heard in this important legal matter.